EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic effects and pharmacokinetics of intravenous penticainide (CM 7857)


European Heart Journal 8(6): 618-623
Electrophysiologic effects and pharmacokinetics of intravenous penticainide (CM 7857)
Penticainide is a new class I antiarrhythmic agent. Its electrophysiological effects and pharmacokinetics properties were studied in 28 patients undergoing endocavitary exploration for paroxysmal supraventricular tachycardia (10 cases), WPW syndrome involving an accessory pathway (5 cases), and unexplained dizziness (13 cases). Increasing doses of penticainide were infused in the first 18 patients (0.12 up to 3.5 mg kg-1). The next ten patient received 4 mg kg-1 over a 30 minute period. Penticainide shortened the sinus cycle length and increased the transnodal conduction time. The vetricular conduction time tended to increase. Atrial functional refractory period increased when atrioventricular nodal and ventricular refractory periods remained unchanged. In patients with previous supraventricular tachycardias all triggered arrhythmias were prevented with dosages higher than 2 mg kg-1 and related blood levels higher than 3 mg l-1. A dose-dependency of plasma and renal clearance was documented. Average Cmax values after 4 mg kg-1 was 7.37 .+-. 1.28 mg l-1. No adverse events occurred during the trial and penticainide proved to be well tolerated.

(PDF 0-2 workdays service: $29.90)

Accession: 005349279

PMID: 3622542



Related references

Electrophysiologic effects of cm 7857 penticainide in patients with bundle branch block. European Heart Journal 8(ABSTR SUPPL 2): 194, 1987

Electrophysiological effects of penticainide (CM 7857) in isolated human atrial and ventricular fibers. Journal of Cardiovascular Pharmacology 13(2): 328-335, 1989

Hemodynamic effects of penticainide (CM 7857), a novel class I antiarrhythmic drug--comparison with disopyramide. Journal of Cardiovascular Pharmacology 12(2): 247-251, 1988

Electrophysiological studies of penticainide (CM 7857), a new antiarrhythmic agent, in mammalian myocardium. Journal of Cardiovascular Pharmacology 9(5): 601-610, 1987

Electrophysiologic effects of penticainide in patients with supraventricular tachycardia. Zeitschrift für Kardiologie 79(10): 725-731, 1990

Influence of food and body weight on the pharmacokinetics of penticainide. Fundamental & Clinical Pharmacology. 8(5): 453-457, 1994

Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. Journal of Veterinary Pharmacology and Therapeutics 20(5): 355-361, 1997

Electrophysiologic effects of intravenous carocainide. Archives des Maladies du Coeur et des Vaisseaux 79(2): 236-241, 1986

Electrophysiologic effects of intravenous metoprolol. American Heart Journal 107(6): 1125-1131, 1984

Electrophysiologic effects of intravenous propafenone. Zhonghua Xin Xue Guan Bing Za Zhi 17(3): 133-6, 189, 1989